Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment

Biochemical and Biophysical Research Communications

Volumn 452, Issue 1, 2014, Pages 157-162

  Knake, Claudia ^a   Stamp, Lisa ^b   Bahn, Andrew ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Furosemide; Gout; miR 448; Oxypurinol; Xanthine oxidase

Indexed keywords

ADENYLATE KINASE; FUROSEMIDE; MICRORNA; MICRORNA 448; OXIPURINOL; PROBENECID; UNCLASSIFIED DRUG; XANTHINE OXIDASE; ALLOPURINOL;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FLUOROMETRY; GOUT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INCUBATION TIME; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; CELL LINE; DRUG INTERACTION;

ALLOPURINOL; CELL LINE; DRUG INTERACTIONS; FUROSEMIDE; GOUT; HUMANS;

EID: 84907846655     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.08.068     Document Type: Article

References (25)

1. L.K. Stamp, M.L. Barclay, J.L. O'Donnell, M. Zhang, J. Drake, C. Frampton, and P.T. Chapman Furosemide increases plasma oxypurinol without lowering serum urate - a complex drug interaction: implications for clinical practice Rheumatology (Oxford) 51 2012 1670 1676
2. T. Spector Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical Biochem. Pharmacol. 37 1988 349 352
3. M.A. Ogryzlo, M.B. Urowitz, H.M. Weber, and J.B. Houpt The treatment of gout and disorders of uric acid metabolism with allopurinol Can. Med. Assoc. J. 95 1966 1120 1127
4. T. Neogi Clinical practice. Gout N. Engl. J. Med. 364 2011 443 452
5. T. Yamamoto, Y. Moriwaki, S. Takahashi, Z. Tsutsumi, and T. Hada Effect of furosemide on renal excretion of oxypurinol and purine bases Metabolism 50 2001 241 245
6. A.J. Reyes Cardiovascular drugs and serum uric acid Cardiovasc. Drugs Ther. 17 2003 397 414
7. M.A. McAdams-DeMarco, J.W. Maynard, A.N. Baer, L.W. Kao, A. Kottgen, and J. Coresh A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study Ann. Rheum. Dis. 72 2013 701 706
8. H. Hasannejad, M. Takeda, K. Taki, H.J. Shin, E. Babu, P. Jutabha, S. Khamdang, M. Aleboyeh, M.L. Onozato, A. Tojo, A. Enomoto, N. Anzai, S. Narikawa, X.L. Huang, T. Niwa, and H. Endou Interactions of human organic anion transporters with diuretics J. Pharmacol. Exp. Ther. 308 2004 1021 1029
9. Y. Hagos, A. Bahn, S.V. Vormfelde, J. Brockmoller, and G. Burckhardt Torasemide transport by organic anion transporters contributes to hyperuricemia J. Am. Soc. Nephrol. 18 2007 3101 3109
10. Y. Hagos, D. Stein, B. Ugele, G. Burckhardt, and A. Bahn Human renal organic anion transporter 4 operates as an asymmetric urate transporter J. Am. Soc. Nephrol. 18 2007 430 439
11. P. Jutabha, N. Anzai, K. Kitamura, A. Taniguchi, S. Kaneko, K. Yan, H. Yamada, H. Shimada, T. Kimura, T. Katada, T. Fukutomi, K. Tomita, W. Urano, H. Yamanaka, G. Seki, T. Fujita, Y. Moriyama, A. Yamada, S. Uchida, M.F. Wempe, H. Endou, and H. Sakurai Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate J. Biol. Chem. 285 2010 35123 35132
12. A.A. El-Sheikh, J.J. van den Heuvel, J.B. Koenderink, and F.G. Russel Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4 Br. J. Pharmacol. 155 2008 1066 1075
13. A.M. Bataille, C.L. Maffeo, and J.L. Renfro Avian renal proximal tubule urate secretion is inhibited by cellular stress-induced AMP-activated protein kinase Am. J. Physiol. Renal Physiol. 300 2011 23
14. B.P. Lewis, C.B. Burge, and D.P. Bartel Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell 120 2005 15 20
15. S.L. Stocker, A.J. McLachlan, R.M. Savic, C.M. Kirkpatrick, G.G. Graham, K.M. Williams, and R.O. Day The pharmacokinetics of oxypurinol in people with gout Br. J. Clin. Pharmacol. 74 2012 477 489
16. N. Anzai, K. Ichida, P. Jutabha, T. Kimura, E. Babu, C.J. Jin, S. Srivastava, K. Kitamura, I. Hisatome, H. Endou, and H. Sakurai Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans J. Biol. Chem. 283 2008 26834 26838
17. H. Uchino, I. Tamai, H. Yabuuchi, K. China, K.-I. Miyamoto, E. Takeda, and A. Tsuji Faropenem transport across the renal epithelial luminal membrane via inorganic phosphate transporter Npt1 Antimicrob. Agents Chemother. 44 2000 4
18. K. Pui, P.J. Gow, and N. Dalbeth Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population J. Rheumatol. 40 2013 872 876
19. P. Xu Repressed expression of the human xanthine oxidoreductase gene. E-box and TATA-like elements restrict ground state transcriptional activity J. Biol. Chem. 275 2000 5918 5926
20. A.M. Bataille, C.L. Maffeo, and J.L. Renfro Avian renal proximal tubule urate secretion is inhibited by cellular stress-induced AMP-activated protein kinase Am. J. Physiol. Renal Physiol. 300 2011 F1327 F1338
21. J. Krol, I. Loedige, and W. Filipowicz The widespread regulation of microRNA biogenesis, function and decay Nat. Rev. Genet. 11 2010 597 610
22. W. Zhang, and M.E. Dolan Emerging role of microRNAs in drug response Curr. Opin. Mol. Ther. 12 2010 14
23. J.L. Rukov, and N. Shomron MicroRNA pharmacogenomics: post-transcriptional regulation of drug response Trends Mol. Med. 17 2011 412 423
24. J. Hausser, A.P. Syed, B. Bilen, and M. Zavolan Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation Genome Res. 23 2013 604 615
25. S. Kitamura, K. Sugihara, and S. Ohta Drug-metabolizing ability of molybdenum hydroxylases Drug Metab. Pharmacokinet. 21 2006 16